PeptideStack
5.2kquestions
20kanswers
220users

What does the mechanism of tirzepatide predict that SURMOUNT-1 did not test?

Asked 16 Dec 2025Modified 7 months agoViewed 7.4k times
17

What I am working with: tirzepatide · SURMOUNT-1.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

What is the causal chain, and where does it stop being established?

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questionsclinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionsgip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
TM
askedtobias_maartens171k35816 Dec 2025
3Is this about the injectable or the oral form? The pharmacokinetics are not comparable. – pascal_thibault 8 months ago
4Same question, and the manufacturer's own page did not answer it either. – bac_or_bust 10 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 7.4k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.